WCWansang Cho

Wansang Cho

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wansang Cho has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Programmable Signaling Drives CAR T Cells to Enhanced Functional States

    by Wansang Cho, Jenny Y. Liu, Ethan E. Chen, Antonio Salcido-Alcántar, Judith C. Lunger, Alex N. Beckett, Erin Craig, Dain R. Brademan, Peng Xu, Katie Ho, et al.

    Cytokine receptors have evolved to use a limited set of conserved signaling motifs to encode remarkably diverse cellular responses. Using 12 signaling motifs, we created Programmable Activators of Cell Signaling (PACS) that activate complex non-natural signaling programs unconstrained by the evolved architecture of natural cytokine receptors. We experimentally tested 457 unique PACS in chimeric antigen receptor (CAR) T cells and trained models to identify PACS features that promote memory, cytotoxicity, and autonomous proliferation. Recombination of signaling motifs created a broad spectrum of signaling and corresponding CAR T cell phenotype. PACS signaling domains serve as a configurable programming layer whose motifs systematically alter STAT phosphorylation to encode cell phenotype. Guided by machine learning models, we rationally designed two PACS with tuned signaling profiles that increase CAR T cell memory and cytotoxicity while reducing toxicity. This work provides a platform for multi-parameter optimization of therapeutic cell functions to improve efficacy and safety.

  • Open Access

    Programmable Activators of Cell Signaling Polarize Macrophages to User-Defined Functional States

    by Judith C. Lunger, Lucas E. Sant&Apos;Anna, Antonio Salcido-Alcántar, Rebeca Arroyo Hornero, Wansang Cho, Alun Vaughan-Jackson, Mingxin Gu, Jenny Y. Liu, Alex N. Beckett, Joaquin Parrilla-Garcia, et al.

    Technology that precisely controls macrophage polarization would deepen our understanding of macrophage biology and enable new macrophage-based cell therapies. Here, we use Programmable Activators of Cell Signaling (PACS), a synthetic receptor platform with modular signaling motifs, to control primary human macrophage polarization. Random recombination of nine distinct signaling motifs generates diverse synthetic macrophage states with varied expression of surface markers and E. coli phagocytosis capacity. PACS programmed with multiple YLxQ motifs increase chimeric antigen receptor (CAR)-macrophage phagocytosis of cancer cells in mice, reducing tumor burden 30-fold. A two-state model describes the motif-dependent polarization well, enabling prediction of macrophage state from PACS signaling domain composition. We apply this model to rationally design a PACS receptor that enables macrophages to adopt a highly phagocytic phenotype while retaining pro-inflammatory activity. Together, these findings establish a framework for synthetic programming of macrophage polarization states, with potential applications in cancer immunotherapy and other disease contexts.

  • Open Access

    Programmable synthetic cytokine receptors polarize macrophages to user-defined functional states

    by Judith C. Lunger, Lucas E. Sant’ANna, Antonio Salcido-Alcántar, Rebeca Arroyo Hornero, Wansang Cho, Alun Vaughan-Jackson, Mingxin Gu, Jenny Y. Liu, Alex N. Beckett, Joaquin Parrilla-Garcia, et al.

    Summary: Technology that precisely controls macrophage polarization to distinct functional states would deepen our understanding of macrophage biology and enable the development of new macrophage cell therapies. Here, we use a synthetic cytokine receptor (SCR) platform with a programmable signaling domain to control the polarization of primary human macrophages. SCRs containing signaling motifs from the interferon-gamma (IFN-γ) or Interleukin-10 (IL-10) receptors mimic key features of pro-inflammatory or anti-inflammatory polarization, respectively. Random recombination of nine distinct signaling motifs to create new SCR signaling domains generates a diverse landscape of synthetic macrophage states with varied expression of inflammatory markers (CD80, CD40) and anti-inflammatory markers (CD163, CD206), and varied phagocytic capacity. SCRs programmed with multiple YLxQ motifs increase macrophage phagocytosis of E. coli and chimeric antigen receptor (CAR)-macrophage phagocytosis of cancer cells in mice, reducing tumor burden by 30-fold. The motif-dependent polarization is well-described by a two-state model, enabling quantitative prediction of macrophage polarization state from SCR signaling domain composition. Leveraging this model, we design an SCR that simultaneously enhances phagocytosis and maintains a macrophage pro-inflammatory state. Together, these findings establish a framework for synthetic programming of macrophage polarization states, with potential applications in cancer immunotherapy and other disease contexts.


  • Open Access

    A continuous landscape of signaling encodes a corresponding landscape of CAR T cell phenotype

    by Wansang Cho, Jenny Y Liu, Alex N Beckett, Judith C Lunger, Peng Xu, Katie Ho, Ethan E Chen, Antonio Salcido-Alcántar, Lucas E Sant’ANna, Kamal Obbad, et al.

    Cytokine signaling is critical to the function of natural immune cells and engineered immune cell therapies such as chimeric antigen receptor (CAR) T cells. It remains unclear how the limited set of signal transducers and activators of transcription (STATs) and other proteins activated by these cytokine receptors can encode the observed diversity of immune cell phenotypes. To understand how signaling downstream of cytokines control immune cell phenotype, we sought to map the structure of Janus kinase (JAK)/STAT signaling domains to cell signaling and resulting CAR T cell function. We recombined 14 signaling motifs to construct a library of ∼30,000 constitutively active synthetic cytokine receptors (SCRs) with intracellular domains composed of novel signaling motif combinations that activate different signaling cascades. We experimentally tested ∼450 SCRs which generated a range of CAR T cell memory, cytotoxicity, and proliferation. SCRs with pSTAT1 and 3 signaling generated effector memory CAR T cells, while SCRs with strong pSTAT5 generated effector CAR T cells with potent anti-tumor activity. To map the structure-signaling-phenotype landscape we trained models to predict signaling and CAR T cell phenotype that result from varied motif combinations. From neural network predictions we identified features, including strong STAT5 and Shc signaling, that promote unsafe autonomous CAR T cell proliferation. Models also revealed a trade-off between memory and cytotoxicity, with a Pareto front encoded by a continuous change in signaling. These results demonstrate that recombination of a limited set of signaling motifs creates a continuous spectrum of signaling that encodes a corresponding spectrum of cell phenotype. This work synthetically expands the combinatorial space of JAK/STAT signaling and provides a foundation for rational design of CAR T cells with improved cytotoxicity, memory, and safety profiles. Abstract Figure:


  • Open Access

    Rational Design of Pyrido[3,2-b]indolizine as a Tunable Fluorescent Scaffold for Fluorogenic Bioimaging

    by Sihyeong Yi, Dahham Kim, Wansang Cho, Jung Ho Lee, Ji Hoon Kwon, Jonghoon Kim, Seung Bum Park

    Novel fluorescent scaffolds are highly demanding for a wide range of applications in biomedical investigation. To meet this demand, the pyrido[3,2-b]indolizine scaffold was designed as a versatile organic fluorophore. With the aid of computational modeling, fluorophores offering tunable emission colors (blue to red) were constructed. Notably, constructed fluorophores absorb lights in the visible range (>400 nm) despite their small sizes (<300 g/mol). Among the fluorophores was discovered a highly fluorogenic fluorophore with a unique turn-on property, 1, and it was developed into a washing-free bioprobe for visualizing cellular lipid droplets in living cells. Furthermore, motivated by the core's compact size and structural analogy to indole, unprecedented tryptophan-analogous fluorogenic unnatural amino acids were constructed and incorporated into fluorogenic peptide probes for monitoring peptide-protein interactions.


  • STING Upregulation Strategies to Potentiate STING Immunotherapy

    by Wansang Cho, Jung Ho Lee, Seung Bum Park


  • Rücktitelbild: Targeted Protein Upregulation of STING for Boosting the Efficacy of Immunotherapy (Angew. Chem. 18/2023)

    by Wansang Cho, Solchan Won, Yoona Choi, Sihyeong Yi, Jong Beom Park, Jun‐Gyu Park, Caroline E. Kim, Chintam Narayana, Ju Hee Kim, Junhyeong Yim, et al.

  • Back Cover: Targeted Protein Upregulation of STING for Boosting the Efficacy of Immunotherapy (Angew. Chem. Int. Ed. 18/2023)

    by Wansang Cho, Solchan Won, Yoona Choi, Sihyeong Yi, Jong Beom Park, Jun‐Gyu Park, Caroline E. Kim, Chintam Narayana, Ju Hee Kim, Junhyeong Yim, et al.

  • Open Access

    Targeted Protein Upregulation of STING for Boosting the Efficacy of Immunotherapy

    by Wansang Cho, Solchan Won, Yoona Choi, Sihyeong Yi, Jong Beom Park, Jun‐Gyu Park, Caroline E. Kim, Chintam Narayana, Ju Hee Kim, Junhyeong Yim, et al.

    Modulating target proteins via the ubiquitin‐proteasome system has recently expanded the scope of pharmacological inventions. Stimulator of interferon genes (STING) is an auspicious target for immunotherapy. Seminal studies envisioned the importance of STING as well as the utility of its agonists in immunotherapy outcomes. Herein, we suggest UPPRIS (upregulation of target proteins by protein‐protein interaction strategy) to pharmacologically increase cellular STING levels for improved immunotherapy. We discovered the small molecule SB24011 that inhibits STING‐TRIM29 E3 ligase interaction, thus blocking TRIM29‐induced degradation of STING. SB24011 enhanced STING immunity by upregulating STING protein levels, which robustly potentiated the immunotherapy efficacy of STING agonist and anti‐PD‐1 antibody via systemic anticancer immunity. Overall, we demonstrated that targeted protein upregulation of STING can be a promising approach for immuno‐oncology.


  • Open Access

    Targeted Protein Upregulation of STING for Boosting the Efficacy of Immunotherapy

    by Wansang Cho, Solchan Won, Yoona Choi, Sihyeong Yi, Jong Beom Park, Jun‐Gyu Park, Caroline E. Kim, Chintam Narayana, Ju Hee Kim, Junhyeong Yim, et al.

    Modulating target proteins via the ubiquitin‐proteasome system has recently expanded the scope of pharmacological inventions. Stimulator of interferon genes (STING) is an auspicious target for immunotherapy. Seminal studies envisioned the importance of STING as well as the utility of its agonists in immunotherapy outcomes. Herein, we suggest UPPRIS (upregulation of target proteins by protein‐protein interaction strategy) to pharmacologically increase cellular STING levels for improved immunotherapy. We discovered the small molecule SB24011 that inhibits STING‐TRIM29 E3 ligase interaction, thus blocking TRIM29‐induced degradation of STING. SB24011 enhanced STING immunity by upregulating STING protein levels, which robustly potentiated the immunotherapy efficacy of STING agonist and anti‐PD‐1 antibody via systemic anticancer immunity. Overall, we demonstrated that targeted protein upregulation of STING can be a promising approach for immuno‐oncology.